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ABSTRACT
Canonical TGF-β1 signalling promotes tumor progression by facilitating invasion 
and metastasis, whereby release of TGF-β1, by (for example) infiltrating immune cells, 
induces epithelial to mesenchymal transition (EMT). PAX2, a member of the Paired 
box family of transcriptional regulators, is normally expressed during embryonic 
development, including in the kidney, where it promotes mesenchymal to epithelial 
transition (MET). PAX2 expression is silenced in many normal adult tissues. However, 
in contrast, PAX2 is expressed in several cancer types, including kidney, prostate, 
breast, and ovarian cancer. While multiple studies have implicated TGF-β superfamily 
members in modulating expression of Pax genes during embryonic development, 
few have investigated direct regulation of Pax gene expression by TGF-β1. Here we 
have investigated direct regulation of PAX2 expression by TGF-β1 in clear cell renal 
cell carcinoma (CC-RCC) cell lines. Treatment of PAX2-expressing 786-O and A498 
CC-RCC cell lines with TGF-β1 resulted in inhibition of endogenous PAX2 mRNA and 
protein expression, as well as expression from transiently transfected PAX2 promoter 
constructs; this inhibition was abolished in the presence of expression of the inhibitory 
SMAD, SMAD7. Using ChIP-PCR we showed TGF-β1 treatment induced SMAD3 protein 
phosphorylation in 786-O cells, and direct SMAD3 binding to the human PAX2 
promoter, which was inhibited by SMAD7 over-expression. Overall, these data suggest 
that canonical TGF-β signalling suppresses PAX2 transcription in CC-RCC cells due to 
the direct binding of SMAD proteins to the PAX2 promoter. These studies improve our 
understanding of tumor progression and epithelial to mesenchyme transition (EMT) 
in CC-RCC and in other PAX2-expressing cancer types.
INTRODUCTION
Approximately 30 Members of the TGF-β 
superfamily, including TGF-βs, activins, bone 
morphogenic proteins (BMPs), anti-Mullerian hormone 
(MIS/AMH), and growth/differentiation factors (GDFs), 
such as myostatin, represent multifunctional cytokines 
secreted by various cell types. TGF-β superfamily ligands 
regulate a vast array of biological processes such as 
growth, differentiation, migration, extracellular matrix 
production, angiogenesis, cytokine secretion, apoptosis, 
setting up of the body plan and organogenesis during 
embryogenesis, tissue homeostasis and immune regulation 
in adults [1–7]. Disruption of TGF-β signalling has been 
implicated in the progression of diseases such as cancer, 
fibrosis and autoimmune disease [8].
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The primary signalling pathway downstream of 
TGF-β superfamily receptor/ligand interactions (for 
instance, interaction of TGF-β1 with type I and type II 
TGF-β receptors [9], and of BMPs with type I and type 
II serine/threonine kinase receptors [10, 11]) involves 
activation of Smad transcription factors [12–16]. In 
response to receptor/ligand interactions, Smad2 or Smad3 
proteins become phosphorylated and form homomeric 
and heteromeric complexes with co-Smads, after which 
the complexes translocate to the nucleus where they either 
directly bind DNA or co-operate with sequence specific 
transcription factors/DNA binding proteins to regulate 
transcription of genes either positively or negatively [17]. 
In opposition to Smad2, or Smad3 effector signalling, 
the vertebrate I-Smads, Smad6 and Smad7 act as 
potent antagonists of TGF-β signalling [18–23] through 
recruitment of either ubiquitin ligases (Smurf1/2), or 
protein phosphatase I, or by becoming part of the TGF-β 
receptor complex and thereby interfering in the formation 
of SMAD2/SMAD3/co-SMAD complexes.
In cancer, TGF-β1 plays a dual role, involving both 
tumor suppressor and oncogenic functions, depending 
on context [24]. For instance, in the early stages of 
tumorigenesis the TGF-β signalling pathway induces 
growth arrest and promotes apoptosis, and mutation or 
deletion of members of the TGF-β signalling pathway 
define a tumor suppressor role for TGF-β signalling [8]. 
In contrast, activation of the TGF-β signalling pathway 
occurs in the late stages of tumorigenesis, as tumor cells 
become more invasive and prone to metastases, which is 
accompanied by induction of epithelial to mesenchymal 
transition (EMT).
During kidney development, ectopic expression 
of Activin A, a member of the TGF-β superfamily, 
inhibits GDNF-induced ureteric bud outgrowth and cell 
proliferation [25], and reduces Pax2 expression [26]. In 
contrast, BMP-7 induces Pax2 expression during kidney 
development [2]. Furthermore, exogenous expression 
of TGF-β1 in dysplastic kidney epithelial-like cells, 
decreased expression of Pax2, which was associated with 
decreased proliferation and transition to a mesenchymal 
phenotype [27]. In addition, TGF-β1 treatment caused 
suppression of Pax2 expression in proximal renal tubule 
cells [28]. Taken together, these data suggest there is an 
interaction between TGF-β1 signalling and Pax2 in kidney 
development and disease.
PAX2 is the second member of the Paired box 
(Pax) gene family, which has critical roles during 
early patterning events of the embryo [29, 30]. PAX2 is 
expressed at a very early stage in the nephric lineage and 
is required for normal kidney development in both mice 
[31, 32] and humans [33]. In early kidney development, 
the induction and conversion of metanephric mesenchyme 
to nephrogenic epithelium has been shown to require 
Pax2 activity during mesenchymal to epithelial transition 
(MET) [32], and this mechanism is also thought to 
operate during kidney regeneration and following kidney 
injury [34]. While Pax2 is only transiently expressed in 
the nephrogenic mesenchyme of the kidney, unabated 
expression of Pax2 leads to abnormal kidney hyperplasia 
and cystogenesis [35].
PAX2 is expressed in multiple different cancer 
types, including in renal cell carcinoma (RCC), ovarian 
cancer, endometrial carcinoma, breast cancer, and prostate 
cancer, [30]. Of these various cancer types, some subtypes 
frequently express PAX2 at high levels, whereas in the 
surrounding normal adult tissue the PAX2 expression is 
repressed following cessation of development [30]. In 
serous ovarian cancer cells wild-type p53 was shown to 
activate PAX2 expression [36]. However, the mechanisms 
by which PAX2 expression is regulated in cancer 
remain relatively poorly understood, and in particular 
the mechanisms associated with repression of PAX2 
expression. For example, PAX2 protein expression has 
been noted at relatively early stages of tumor formation 
in serous ovarian carcinoma, but at later stages of 
progression the acquisition of metastasis is accompanied 
by loss of PAX2 expression [36]. Concomitantly, the loss 
of epithelial differentiation is associated with increased 
levels of TGF-β1 and TGF-β signalling in higher grades of 
ovarian cancer [37]. In serous ovarian carcinoma, down-
regulation of PAX2 expression during later stages of tumor 
development in secretory cell outgrowths (SCOUTs) has 
been identified, and members of the TGF-β downstream 
signalling pathway were expressed in the same cells 
[38, 39].
In RCC, loss of VHL and hypoxia has been shown 
to activate PAX2 expression [40], but the potential role 
of PAX2 expression in RCC at later stages of tumor 
development is less well understood. PAX2 expression is 
also associated with several other kidney abnormalities, 
such as renal interstitial fibrosis [41] and polycystic kidney 
disease [42]. Following kidney injury, generation of renal 
fibrosis or scar tissue is dependent on the expression of 
TGF-β [43] and eventually, EMT-dependent suppression 
of PAX2 expression following its transient activation [41, 
44]. Moreover, PAX2 expression in RCC has been shown 
to promote the expression of ADAM10, which is a negative 
regulator of EMT, and suggests further an association 
between PAX2 and suppression of EMT in RCC [45].
In this study we investigated the potential role of 
TGF-β1 signalling in promoting down-regulation of 
PAX2 expression in RCC tissue. We have identified a 
direct role for SMAD proteins in binding to the PAX2 
gene promoter to suppress PAX2 expression in human 
clear cell renal cell carcinoma (CC-RCC) cells, during 
canonical TGF-β signalling. This finding suggests there 
is a direct relationship between TGF-β1 signalling and 
PAX2 expression during RCC tumor progression, with the 
implication that direct suppression of PAX2 expression in 
some cancer cell types by TGF-β1 signalling is a corollary 
of the promotion of EMT, tumor invasion and metastasis.
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RESULTS
Treatment of RCC cancer cell lines with TGF-β1 
leads to suppression of PAX2 mRNA and 
protein levels
Treatment of PAX2 expressing RCC cell lines, 
786-O and A498 (Figure 1A, 1B), with 10 ng/ml 
TGF-β1 for 24 h resulted in substantial suppression of 
PAX2 mRNA and protein levels (Figure 1C-1E), and 
further analysis revealed significant inhibition of PAX2 
mRNA and protein expression in 786-O cells in response 
to increasing concentrations of TGF-β1, which was 
sustained from 6 h to more than 48 h after treatment 
(Figure 1E, Supplementary Figure 1). The results of 
these investigations are consistent with previous studies, 
suggesting that TGF-β signalling pathways inhibit Pax 
gene expression [46].
Figure 1: TGF-β1 treatment suppresses PAX2 mRNA and protein expression in CC-RCC cell lines. (A) Western blot 
analysis of PAX2 protein expression in RCC cell lines. GAPDH was used as a loading control. (B) QRT-PCR analysis of the relative level 
of endogenous PAX2 mRNA in HEK293 and three CC-RCC human cell lines. The data represent three separate experiments. (C) Relative 
PAX2 mRNA expression level, and (D) PAX2 protein following treatment of 786-O and A498 CC-RCC cells with 10 ng/ml TGF-β1 
(labelled “+”, black columns) versus vehicle treated controls (labelled “-“, white columns). The results from three separate experiments 
after normalisation with GAPDH are shown. (E) Western blot of PAX2 protein expression relative to GAPDH following no treatment (0 
h) of 786-O cells, or treatment for 6, 24 or 48 h with 10 ng/ml TGF-β1. Data are represented as mean ± S.E.M. The data were analysed by 
Student’s t test using GraphPad Prism 5.01, ** p < 0.01, *** p < 0.001 versus controls.
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TGF-β1 treatment suppresses PAX2 promoter 
activity in RCC cells
To determine whether TGF-β treatment mediates 
inhibition of PAX2 expression directly or indirectly via 
regulation of the PAX2 promoter, we investigated whether 
TGF-β1 treatment could suppress transiently transfected 
human PAX2 promoter constructs in kidney and RCC 
cell lines. Previous studies have shown that there is 
potential for positive transcriptional auto-activation 
on PAX gene promoters by PAX proteins [46, 48]. We 
therefore reasoned that it would be important to minimize 
any potential confounding effects of auto-regulation on 
TGF-β1- mediated PAX2 suppression. HEK293 (human 
embryonic kidney), or TK10 (CC-RCC) cell lines have 
previously been shown to express little or no endogenous 
PAX2 mRNA or protein [47] (Figure 1). We found that 
PAX2 promoter-luciferase reporter constructs (pGPxp17 
and pGPxp2, Figure 2A) were transcriptionally active in 
the HEK293 and TK10 cell lines (Figure 2), suggesting 
that these cells would be suitable to carry out the reporter 
assays. The pGPxp17 and pGPxp2 promoter-reporter 
constructs were transiently transfected into the HEK293 
and TK-10 cells, which were then treated for 24 h with 10 
ng/ml TGF-β1. Luciferase reporter activity was suppressed 
by the TGF-β1 treatment (Figure 2B, 2C), suggesting that 
TGF-β1 treatment caused transcriptional suppression 
of the PAX2 promoter construct activity in the transient 
transfection assays.
Expression of SMAD-7 in RCC cells abolishes 
the inhibitory effect of TGF-β1 on PAX2 protein 
and mRNA expression
We next investigated whether signalling via SMAD 
proteins, which are known to mediate canonical TGF-β1 
signalling, could be involved in the transcriptional 
suppression of PAX2 by TGF-β1. Exposure of 786-O 
cells to TGF-β1 for 6 h, 24 h or 48 h led to the strong 
phosphorylation of SMAD3 protein (Figure 3A), 
consistent with the expected effects of TGF-β1 treatment. 
Evidence for the involvement of SMAD proteins in the 
Figure 2: TGF-β1 treatment suppresses PAX2 promoter activity in CC-RCC cell lines. (A) The PAX2 promoter reporter 
constructs (pGPxp17 and pGPxp2) are shown. (B) HEK293 or (C) TK10 cells were transiently transfected with PAX2 promoter constructs 
(pGPxp17 or pGPxp2) and treated with 10 ng/ml TGF-β1 and the luciferase activity was assayed in TGF-β1 treated (grey columns) versus 
cells treated with vehicle control (white columns) The data represent the mean ± S.E.M of at least three experiments and were analyzed by 
Student’s t test (**, p < 0.01). HEK293 (n=5), TK10 (n=4).
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Figure 3: The canonical SMAD signalling pathway is involved in the regulation of PAX2 by TGF-β1 in 786-O cells. (A) 
Following treatment with TGF-β1, downstream SMAD3 becomes phosphorylated at carboxyl terminal serine residues. The phosphorylation 
of SMAD3 was determined in vehicle (-) and TGF-β1 (+) treated 786-O cells at 6 h, 24 h and 48 h post stimulation using phospho-
Smad3 antibody, which detects endogenous levels of Smad3 when phosphorylated at Ser423/425. GAPDH served as a loading control. (B) 
Phosphorylation of SMAD3 upon treatment with TGF-β1 was associated with inhibition of PAX2 expression, and PAX2 suppression was 
abrogated upon expression of the iSMAD, SMAD7. (C) Quantitation of the PAX2 protein levels and (D) PAX2 mRNA levels in 786-O cell 
as treated in (B) in two separate experiments after normalization with GAPDH or with housekeeping genes relative to vehicle treated cells 
(with the PAX2 expression level set to 1). The data are represented as mean ± S.E.M. and were analyzed by one-way ANOVA followed by 
Tukey’s multiple comparison post-test (***, p < 0.001 versus control cells). The first column represents cells with no transfection and the 
dark grey (column 3) represents cells transiently transfected with the SMAD7-FLAG expression construct, while the lighter grey (columns 
2 and 4) represent respective cells treated with TGF-β1.
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regulation of PAX2 expression was obtained by expressing 
an inhibitory SMAD (SMAD7), which we predicted 
would abolish the suppressive effect of TGF-β signalling 
on PAX2 expression levels if indeed SMAD signalling 
was involved in suppressing PAX2 transcription. To 
investigate this, 786-O cells were transiently transfected 
with an inhibitory SMAD7 expression construct, or an 
empty expression vector, then treated with either TGF-β1 
or vehicle 24 h post-transfection. After transfection the 
cells were analyzed for relative levels of PAX2 protein and 
mRNA expression a further 48 h later. The treatment of 
786-O cells with TGF-β1 suppressed PAX2 protein levels 
by 50 +/- 0.03% (p<0.001) and PAX2 mRNA by 60 +/- 
0.03% (p<0.001) in the absence of SMAD7 (Figure 3B, 
lane 2), but in the presence of SMAD7, TGF-β1 treatment 
did not significantly suppress either levels of PAX2 
protein (Figure 3B, lane 4 and Figure 3C), or PAX2 mRNA 
(Figure 3D). SMAD3 phosphorylation was observed 
following TGF-β1 treatment of 786-O cells, irrespective 
of the presence of SMAD7 expression (Figure 3B, lanes 
2 and 4). These data suggest that SMAD proteins are 
directly associated with suppression of PAX2 expression, 
as the suppression of PAX2 by TGF-β1 treatment, which 
was associated with phosphorylation of SMAD3, was 
overcome by overexpression of the inhibitory SMAD 
(SMAD7) in 786-O cells.
Is there a physical interaction between PAX2 
and SMAD2 or SMAD3?
SMAD proteins have been shown to physically 
interact with PAX6 protein, preventing PAX6 from auto-
activating its own gene promoter [46, 48]. We therefore 
next determined whether SMAD proteins interact with the 
PAX2 protein, but we first sought to determine whether 
PAX2 auto-activates its own promoter. HEK293 cells were 
transiently co-transfected with 150 ng of PAX2 promoter-
luciferase reporter construct and PAX2 expression 
constructs. We observed increased PAX2 promoter-
luciferase activity (~444,000 to 449,000 RLU for PAX2b 
and PAX2c, respectively) in these co-transfections 
compared to the co-transfection of the equivalent amount 
of PAX2 promoter-luciferase reporter and empty vector 
expression constructs (~118,000 RLU, Figure 4A, 
4B). When co-transfected promoter-luciferase reporter 
construct, pGPxp2, was increased to 425 ng, while 
maintaining PAX2b or PAX2c at 150 ng, this resulted in a 
further increase in luciferase activity (~620,000 to 670,000 
RLU for PAX2b and PAX2c, respectively). In addition, 
when pGPxp2 was maintained at 150 ng, while increasing 
the PAX2b or PAX2c to 425 ng, this also resulted in 
increased luciferase activity (~300,000 RLU for either 
PAX2b and PAX2c). These results suggest that PAX2 
auto-activates its own promoter. It is therefore possible 
that, like Pax6, SMAD proteins could interact directly 
with the PAX2 protein and thereby prevent auto-activation 
of the PAX2 promoter, as had been demonstrated for TGF-
β1-mediated regulation of Pax6 expression [46, 48]. To 
investigate this, we carried out co-immunoprecipitation 
using an anti-SMAD2/3 antibody to determine whether a 
direct protein-protein interactions occurs between SMAD2 
or SMAD3 proteins and the PAX2 protein. No evidence 
was found for an interaction between SMAD2/3 and PAX2 
proteins (Figure 4B). In contrast, there was evidence of a 
potential interaction between SMAD2/3 and PAX6 protein 
(Supplementary Figure 3), as reported previously [48].
SMAD3 directly binds to the PAX2 promoter in 
RCC cells in response to TGF-β1 treatment
We next investigated whether SMAD3 could bind 
directly to the PAX2 promoter. Using the binding site 
prediction tool, ConTra v.2, at least seven SMAD (SMAD1 
or SMAD3) binding sites were predicted in the ~1Kb of 
the PAX2 promoter upstream of the transcription start site 
(TSS), or in the 5’ untranslated region (5’UTR) (Figure 
5A). Promoter-ChIP-PCR binding assays were used to 
investigate the binding of SMAD2 or SMAD3 proteins 
directly to the PAX2 promoter following TGF-β1 treatment 
in both 786-O and HEK293 cells, and an approximately 
4 to 5-fold enrichment of SMAD2/3 binding to PAX2 
promoter fragments was observed (p<0.001) (Figure 5B, 
5D). Although the individual binding sites could not be 
resolved by the binding of SMAD proteins in the PAX2 
promoter in ChIP analysis, since individual sonicated 
fragments were between 200-800 bp in length and 
potentially encompassed multiple SMAD binding sites, the 
results nevertheless suggested that significantly increased 
binding of SMAD proteins to the PAX2 promoter occurred 
in cells treated with TGF-β1. As a negative control the 
GNB2L1 gene promoter was investigated, which contains 
no SMAD binding site in its promoter, and no enrichment 
of SMAD2 or SMAD3 binding was observed following 
TGF-β1 treatment in either 786-O or HEK293 cells 
(Figure 5B, 5D). We then investigated the effects of the 
inhibitory SMAD, SMAD7 on binding of SMAD2/3 
to the PAX2 promoter. The 786-O or HEK293 cells 
were transiently transfected with a SMAD7 expression 
construct, and the promoter-ChIP-PCR binding assays 
were again carried out. Following expression of SMAD7, 
the SMAD2/3 binding was inhibited (Figure 5C, 5E). 
These ChIP-PCR results suggest that SMAD3 protein 
is able to bind directly to DNA fragments within a 1Kb 
region of the PAX2 promoter in ChIP-PCR binding assays, 
and that this binding is inhibited upon overexpression of 
SMAD7.
DISCUSSION
Here we show that TGF-β1 treatment of renal 
cell carcinoma cells is associated with transcriptional 
supression of PAX2, through the direct binding of 
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SMAD proteins to the PAX2 promoter. Although our 
ChIP data demonstrate binding of SMAD3 to the PAX2 
promoter, these results do not distinguish which sites 
are functional, and further work will be required to 
determine this. Nevertheless, these findings represent the 
first evidence for direct promoter-mediated inhibition of 
PAX2 expression by TGF-β1 signalling in tumor cells. 
With respect to several other Pax family members, it has 
previously been shown that TGF-β signalling regulates 
Pax6 or Pax8 gene expression through protein-protein 
interactions between SMAD2/3 and the Pax protein, 
resulting in inhibition of auto-activation of the respective 
Pax gene promoter [48, 49]. In contrast, our findings 
suggest that, in the case of PAX2 expression in CC-RCC, 
SMAD2/3 proteins directly bind to the gene promoter, 
resulting in PAX2 transcriptional supression.
Many previous studies have shown that SMAD3 
binding to gene promoters is often associated with 
target gene activation. While the mechanism by which 
the binding of SMADs to the PAX2 promoter leads to 
transcriptional suppression in CC-RCC cells has not 
been elucidated, SMAD proteins have been shown to 
interact with, and are able to form transcriptionally 
inactive complexes with co-repressors in kidney cells 
Figure 4: The PAX2 protein positively auto-regulates its own gene promoter, but does not physically interact with 
SMAD2/SMAD3 proteins. (A) Demonstration of auto-regulation of the PAX2 promoter in HEK293 cells. HEK293 cells were co-
transfected with 150 ng of the PAX2 promoter plasmid (pGPxp2) together with pCMV-empty vector (“pGPxp2 + pCMV-EV”), which 
resulted in moderate luciferase activity (118,300 RLU). However, when HEK293 cells were co-transfected with 150 ng of PAX2 promoter 
reporter construct, pGPxp2, together with 150 ng of PAX2 expression construct, either pCMV-PAX2b (PAX2b, dark grey bar; 449,375 
RLU), or pCMV-PAX2c (PAX2c, light grey bar; 444,159 RLU), there was 3.75-3.8-fold increased luciferase activity induced compared to 
pGPxp2 + pCMV-EV co-transfection. The graph summarizes three separate experiments for each co-transfection. The amounts of all PAX2 
promoter-reporter or PAX2 expression construct plasmid that were used in the graph were 150 ng, unless otherwise specified. Error bars 
show the standard error of the mean. (B) Investigation of protein-protein interactions between PAX2 and SMAD2 or SMAD3. Lane 1: Eluate 
from beads used for pre-clearing the lysate. Lane 2: Input. Lane 3: Eluate from beads, which captured the protein complexes incubated 
with anti-IgG antibody. Lane 4: Eluate from beads, which captured the protein complexes incubated with anti-SMAD2/3 antibody. The 
figure shows that in lane 4, PAX2 was not immunoprecipitated with anti-SMAD2/3 antibody, suggesting there was no functional interaction 
between PAX2 and SMAD2 or SMAD3. The experiment was repeated twice. IgG HC: IgG heavy chain.
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Figure 5: The binding of SMAD3 to the PAX2 promoter in response to TGF-β1 treatment is inhibited in the presence 
of SMAD7 overexpression. (A) Representation of the human PAX2 promoter (not drawn to scale) showing SMAD1 or SMAD3 binding 
sites predicted using ConTra v2, and PCR fragments used for PCR-ChIP assays. Putative SMAD3 binding sites were identified at sites 
4 and 6, while the remaining sites predicted by the ConTra binding site prediction tool were putative SMAD1 binding sites. The “TSS” 
shows the transcription start site. In (B) to (E) ChIP assays were carried out in 786-O and HEK293 cells following TGF-β1 treatment to 
show binding of SMAD3 to PCR-amplified fragments the PAX2 promoter. Sites 6 and 7 in the PAX2 promoter were unable to be amplified 
and were not analysed, but all other sites (sites 1-5) were investigated. In parallel experiments ChIP assays were carried out in cells 
transfected with a SMAD7-FLAG expression construct (see Supplementary Figure 2 for confirmation of SMAD7 overexpression in 786-
O and HEK293 cells). A region of the GNB2L1 promoter without any putative SMAD3 binding site was used as a negative control. Dark 
grey columns represent fold enrichment (over no antibody controls) in cells stimulated with vehicle and lighter grey columns represent fold 
enrichment in cells stimulated with TGF-β1. The data represent the mean ± S.E.M of three independent experiments and were analyzed 
by one-way ANOVA followed by Tukey’s multiple comparison post-test (***, p < 0.001 versus negative control and vehicle treated cells).
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[50]. It is therefore possible that in CC-RCC cells the 
binding of SMADs to the PAX2 promoter interferes with 
factors transcriptionally activating the promoter, which 
then leads to suppression of promoter activation, similar 
to the suppression of C/EBPβ- and STAT3-mediated 
transcriptional activation of the haptoglobin promoter 
by SMAD proteins, which has previously been reported 
[51]. However, it is presently unknown which factors 
are involved in generating the PAX2 promoter activity 
observed in vitro in RCC cells.
The findings reported here are of potential 
importance in understanding the role of PAX2 expression in 
cancer progression and metastasis. Dysgulated expression 
of PAX2 has been linked to several cancer types, including 
RCC, ovarian cancer, endometrial cancer, prostate cancer, 
breast cancer, melanoma, medulloblastoma and Wilms 
tumor [30]. While PAX2 expression has been shown to 
promote tumor cell proliferation and survival in multiple 
cancer types, paradoxically in serous ovarian cancer it 
has been shown that at advanced tumor stages, with onset 
of invasion and metastasis, PAX2 mRNA and protein 
expression decline, and eventually PAX2 expression is 
lost in the invading cells [36]. This apparent selection 
against PAX2 expression within subpopulations of tumor 
cells seems counter-intuitive to the notion that PAX2 
plays an oncogenic role in tumorigenesis. However, it is 
possible that switching away from PAX2 expression might 
reflect characteristic physiological changes within the 
cells, associated with acquisition of invasive properties. 
In serous ovarian cancer, the down-regulation of PAX2 
expression occurs in the secretory outgrowths (termed 
SCOUTs), in which aggressive changes have been 
documented to occur [38, 39, 52]. These outgrowths are 
associated with poorer patient prognosis and progression 
to metastasis. Interestingly, Pax2 is expressed normally in 
mouse adult oviduct tissue [47], and it has been shown 
that Pax2 expression maintains the differentiation of 
adult mouse oviduct epithelium and inhibits the transition 
Table 1: Oligonucleotide primers used for qRT-PCR
Target gene Forward primer 5’- 3’ Reverse primers 5’ – 3’
PAX Genes   
PAX2 CCTGGCCACACCATTGTTC TCACGTTTCCTCTTCTCACCAT
SMAD Genes   
SMAD2 TATGGACACAGGCTCTCCAG CACCAAAATGCAGGTTCTGA
SMAD3 GCAGGTTCTCCAAACCTATCC AGGAGATGGAGCACCAGAAG
Housekeeping Genes   
GAPDH CTCAAGATCATCAGCAATGCC GGTCATGAGTCCTTCCACGATAC
GNB2L1 CACAACGGGCACCACCAC CACACACCCAGGGTATTCCAT
HPRT1 ATTATGGACAGGACTGAACGTCTTG TGAGCACACAGAGGGCTACAAT
RPL32 AACGTCAAGGAGCTGGAAGTG GGCTTTGCGGTTCTTGGA
RPL13a GGAAAGAGAAAGCCAAGATCCA GCTCAGACCAGGAGTCCGTG
YWHAZ ACTTGACATTGTGGACATCGGATAC GTTGGAAGGCCGGTTAATTTTC
PPIB ATGATCCAGGGCGGAGACTT CAGGCCCGTAGTGCTTCAG
Table 2: Oligonucleotide primers used for ChIP-PCR analysis
Target 
Gene
Accession no./
Reference Promoter region Forward sequence 5’–3’ Reverse sequence 5’–3’
PAX2 4842, NM_000278 -997/-819, site 1 GGATCCACCGAGCTAGCAG GGGACTTGGTTTCTGAACCC
PAX2 4842, NM_000278 -838/-657, site 2 GGGTTCAGAAACCAAGTCCC GTCTTGTCCCCTCCCGTTCC
PAX2 4842, NM_000278 -534/-276, site 3 GCTGGGCGAGTTAGAACTGA GCCCGGGATTAAAACTACACTG
PAX2 4842, NM_000278 -115/8, site 4 TGGCGAATCACAGAGTGGTGGAAT GCTCCCGGTGTGTGTCTCTCTAAAA
PAX2 4842, NM_000278 -28/141, site 5 GGGCTTTGCAGCTTTTAGAGAG GGAAAAGGCAGGCGCACG
GNB2L1 33871, NM_006098 -259/-134, GNB2L1 ACTTCACCTCTTTCGCTTCTCGCT ACAGTCCCGTCTTCCGTACAACAA
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to a stem cell-like state [53]. Similarly in breast cancer, 
expression of PAX2 has been associated with a low 
invasive phenotype in luminal breast cancer cells [54], 
while in endometrial cancer joint loss of PAX2 and 
PTEN expression was associated with progression to 
carcinoma [55].
PAX2 protein expression has been associated with 
81-95% of CC-RCCs [56, 57], and we have also shown that 
in vivo tumorigenicity of RCC cells is reduced following 
siRNA-mediated knockdown of PAX2 expression [58]. 
Moreover, PAX2 protein is strongly expressed in primary 
CC-RCC in a high percentage (~66%) of tumor cells, and 
in CC-RCC metastases expression of PAX2 appears to be 
more intense and in a higher proportion (~80%) of tumor 
cells [57]. However, PAX2 expression has been shown 
to positively regulate expression of ADAM10 in CC-
RCC [45], and the suppression of ADAM10 expression is 
associated with EMT, as well as up-regulation of Slug, 
and down-regulation of E-Cadherin expression [45]. In 
independent experiments we observed that, following 
siRNA-mediated silencing of PAX2 expression in A498 
RCC cells, down-regulation of ADAM10 mRNA levels 
occurred (unpublished data), which is in agreement with 
previously published work [45]. Down-regulation of PAX2 
expression as a result of enhanced TGF-β1 signalling in 
CC-RCC would thus be consistent with a role for PAX2 
in facilitating EMT-related changes at least in part via 
reduced ADAM10 expression. Importantly, an increased 
level of TGF-β1 signalling has clearly been associated 
with increased invasion and metastatic changes in CC-
RCC [59–63]. However, in contrast to ovarian cancer 
where PAX2 expression is reduced in SCOUTs, the high 
levels of PAX2 expression observed in metastatic sites of 
CC-RCC [57] seem to contradict the notion that decreased 
PAX2 expression is associated with EMT in CC-RCC. 
Furthermore, it has been observed that PAX2 expression 
levels are increased by hypoxia and VHL mutations in CC-
RCC [40], and so further investigations will be required 
to determine how the TGF-β1/SMAD-mediated signalling 
pathway promotes invasion through modulation of PAX2 
expression in CC-RCC.
We propose that pathways involving TGF-β1 
signalling, and subsequent down-regulation of PAX2 
expression facilitate the switching of tumor cells from 
PAX2-mediated epithelial cell differentiation to more 
stem cell-like mesenchymal programs. These are 
associated with EMT, and greater dependence on other 
signalling pathways, in which tumor cells have acquired 
increased motility, invasiveness and treatment resistance 
[36]. Suppression of PAX2 expression with concomintant 
EMT-related changes might be applicable to multiple 
cancer types in which PAX2 is expressed, including RCC, 
ovarian, breast, endometrial and prostate cancer. It is 
conceivable, however, that the therapeutic inhibition of 
PAX2 could induce tumor progression and metastasis in 
some cancer types, particularly if continued expression 
of PAX2 has a role in promoting epithelial differentiation 
and suppression of tumor metastasis in advanced stages 
of cancer. Although not investigated here, mechanisms 
involving TGF-β signalling, and suppressed expression 
of PAX2 might also be the case in renal fibrosis, where a 
role for PAX2 expression in kidney injury has also been 
identified [41]. In contrast, TGF-β–mediated suppression 
of PAX2 expression might not be universal to all cancer 
types. For example, increasing levels of PAX2 expression 
have been linked to metastatic progression in esophageal 
cancer [64].
In conclusion, our studies have demonstrated that 
TGF-β1 signalling in CC-RCC cells results in the direct 
inhibition of PAX2 expression through SMAD-mediated 
transcriptional suppression of the PAX2 gene promoter. 
These data therefore provide clearer understanding of 
the role of TGF-β1 signalling and PAX2 expression in 
cancer.
MATERIALS AND METHODS
Cell cultures and TGF-β1 treatment
Cell lines used in this study were HEK293 (human 
embryonic kidney immortalized with adenovirus 5 DNA), 
A498, ACHN, CAKI-1, 786-O, 769-P, RXF-393, and 
TK10 (renal cell carcinoma cell lines) and were obtained 
from the Developmental Therapeutics Program, NIH (as 
part of the NCI-60 cell line panel), and cultured either in 
Dulbecco’s Modified Eagle’s Media (DMEM) (Invitrogen, 
USA) or in Roswell Park Memorial Institute (RPMI) 1640 
medium (Invitrogen, USA) supplemented with 10% fetal 
bovine serum (FBS) at 37°C in a humidified environment 
with 5% CO
2
. Cells were seeded at 50-60% confluence, 
and in some experiments were incubated with recombinant 
human TGF-β1 (R & D systems, Minneapolis, MN) at a 
concentration of 10 ng/ml (whenever the concentration 
was not specified). Control cells were treated with vehicle 
(4 mM HCl containing 1 mg/ml bovine serum albumin). 
Cells were harvested at 24 h post TGF-β1 treatment for 
RNA extraction and at 48 h post TGF-β1 treatment for 
Western blot analysis.
Plasmids and promoter reporter constructs
Luciferase reporter plasmids (pGPxp17 and 
pGPxp2) have been reported elsewhere [65], and contained 
the human PAX2 gene promoter fused to the luciferase 
reporter gene of pGL2 basic vector (Promega, USA). The 
pGPxp17 and pGPxp2 plasmids contain 4.2 kb and 1.7 kb 
of the human PAX2 promoter and 5’ – flanking sequences, 
respectively. Expression plasmids encoding PAX2 and 
inhibitory SMAD, SMAD7 (pSMAD7-FLAG) were 
described previously [66, 67]. A plasmid encoding 
β-galactosidase (βgal) under the CMV promoter (pCMV-
βgal) was used as an internal control of transfection 
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efficiency in all reporter assays. Plasmids used for 
transient transfections were prepared using Qiagen 
plasmid Midi/Maxi kits, according to the manufacturer’s 
instructions (Qiagen, Chatsworth, CA).
Luciferase reporter assays
Luciferase reporter assays were carried out 
following transient transfection of cells with promoter-
luciferase reporter constructs as previously described [65]. 
Briefly, cells were plated in 24-well plates to give 30-50% 
confluence after 24 h, and transfections were carried out 
using FuGENE® 6 Transfection Reagent (Roche Applied 
Science, Germany) according to the manufacturer’s 
instructions. An optimal FuGENE (μl): DNA (μg) ratio 
of 6:1 was used for all cell types except TK10 cells for 
which the FuGENE: DNA ratio was 3:1. Control cells 
were transfected with an equal amount of pGL2 basic to 
measure background luciferase activity. Fifty nanograms 
of pCMV-βgal was co-transfected as an internal control for 
transfection efficiency and used for normalizing the data. 
Transfected cells were treated with 10 ng/ml TGF-β1 24 
h after transfection, and cells were harvested at 48 h post 
TGF-β1 treatment. Luminescence was measured using the 
Synergy 2 Multi-Mode Microplate Reader (BioTek, USA) 
and Gen5 interface software (version 1.01.9).
β-galactosidase activity assays
β-galactosidase assays were carried out as described 
previously [67]. Briefly, 10 μl lysate was incubated with 
100 μl βgal substrate solution (200 mM sodium phosphate 
buffer pH 7.3, 2 mM MgCl
2
, 100 mM β-mercapthoethanol, 
1.33 mg/ml ONPG (Sigma-Aldrich). The samples were 
incubated at 37°C until the appearance of a bright yellow 
colour. The absorbance of the reaction was measured at 
410 nm, using the Synergy 2 plate reader.
Total RNA purification and quantitative  
real-time PCR (qRT-PCR)
Total RNA for gene expression analysis was 
isolated as described previously [47]. Briefly, cells were 
lysed with 200 μl TRIzol reagent (Invitrogen, USA) per 
well of a 24-well plate. Total RNA was extracted using 
1-bromo-3-chloropropane (BCP) (Molecular Research 
Centre, USA) and 70% ethanol (in DEPC-H
2
O) (ethanol, 
Sharlau, Spain; DEPC, Sigma-Aldrich, USA) then 
purified using the PureLink RNA Mini Kit (Invitrogen, 
USA) according to the manufacturer’s instructions. 200 
ng of total RNA from each sample was used for generating 
cDNA in a 20-μl reaction. First-strand cDNA was 
synthesized using a SuperScript III Reverse Transcriptase 
Kit (Invitrogen, USA), primed with dNTPs and 250 ng 
random hexamers (Invitrogen, USA), according to the 
enzyme manufacturer’s instructions, and was performed 
at 25°C for 5min, 50°C for 1 hr, and 70°C for 15 min. 
Three microliters of first strand cDNA (diluted 1:10) and 
0.2 μM gene-specific primers (Table 1) were used with 
the Platinum® SYBR® Green qPCR SuperMix UDG 
(Invitrogen, USA), to amplify and detect target genes. 
The qRT-PCR reactions were performed in an ABI-7300 
Real time PCR system (Applied Biosystems, USA) in 
duplicates, using the following program: 50°C – 2 min, 
95°C – 10 min, 45 cycles of 95°C – 15 sec and 60°C – 1 
min, with an additional dissociation stage: 95°C – 15 sec, 
60°C – 1 min, and 95°C – 15 sec. Relative gene expression 
data were normalised to three housekeeping genes, and 
represented relative to vehicle treated control cells. Gene-
specific primers (Invitrogen) for qRT-PCR analysis were 
designed using Primer3 (version 0.4.0, http://frodo.wi.mit.
edu/primer3/). In each QRT-PCR experiment, the three 
most stable housekeeping genes (also listed in Table 1) 
were identified.
Total protein sample preparation, SDS-PAGE 
and western blotting
Protein isolation and Western blots were performed 
as previously described [68]. Briefly, cells were lysed 
in RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS supplemented with protease inhibitors (Complete, 
Roche; 1 mM PMSF, Sigma-Aldrich; 1mM sodium 
orthovandate, Sigma-Aldrich). Total protein in the extracts 
was quantitated using a colorimetric BCA Protein Assay 
Kit as per the manufacturer’s instructions. 40 μg of total 
cellular protein for each sample was boiled in Laemmli 
sample buffer and separated by SDS-PAGE under 
reducing conditions and transferred to nitrocellulose 
membrane (Hybond-C Extra). Immunoreactive bands 
were visualized by chemiluminescence using SuperSignal 
West Pico Chemiluminescent Substrate (containing equal 
parts of the Stable Peroxide Solution and the Luminol/
Enhancer Solution) (Thermo Scientific, USA). Antibodies 
used for Western blotting were rabbit anti-PAX2 (1:500; 
Zymed), mouse anti-SMAD2/3 (1:1000; Santa Cruz 
Biotechnology), goat anti-GAPDH (1:2000, Santa 
Cruz Biotechnology), and anti-rabbit and anti-mouse 
horseradish peroxidase IgG (Sigma-Aldrich). The protein 
ladder used was MagicMark XP Standard (Invitrogen, 
USA).
Chromatin immunoprecipitation (ChIP)-PCR
ChIP-PCR assays were carried out as described 
in Sehgal et al (2009) [69] with several modifications. 
Briefly, approximately 1.0 x 108 cells, with or without 
TGF-β1 treatment, were crosslinked per ChIP analysis. 
Following washing, scraping and centrifugation of the 
cells in ice cold PBS, the cells were then lysed in 50 mM 
Tris-HCl pH 8.0, 10 mM EDTA, 1% SDS supplemented 
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with protease inhibitors (Complete, Roche; 1 mM PMSF, 
Sigma-Aldrich; 1mM sodium orthovandate, Sigma-
Aldrich). The lysates were then sonicated to obtain DNA 
fragments in the range of 200-800 bp using a Sonics Vibra-
Cell sonicator (Sonics and Materials Inc., USA, Model: 
VCX 130) set to 25% amplitude. HEK293 cells were 
sonicated for 5 sets of 10-second pulses and 786-O cells 
for 5 sets of 20-second pulses. Following centrifugation 
(12,000 x g, 10 min at 4°C) supernatants were diluted 
2.5 times with ChIP dilution buffer (0.5% Triton X-100, 
2 mM EDTA, 20 mM Tris-HCl pH 8.0, 100 mM NaCl), 
and 5% of the diluted supernatant was saved as an Input 
control. The rest of the supernatant was precleared using 
Dynabeads® Protein G (Invitrogen) for 1 h at 4°C. For 
immunoprecipitation 4 μg of anti-SMAD2/3 (Santa Cruz 
Biotechnology) was added to precleared lysates and 
rotated at 4°C overnight. Lysates with no antibody served 
as a negative control. The remainder of the protocol was 
carried out essentially as described in Sehgal et al (2009). 
The qRT-PCR reactions were performed as described 
previously (ChIP PCR primers listed in Table 2) except an 
additional dissociation was performed at 99°C instead of 
95°C. The data were analysed according to the SuperArray 
ChIP-qPCR Data Analysis Template (www.sabiosciences.
com/manuals/chipqpcranalysis.xls). Individual binding 
sites were unable to be resolved by the binding of SMAD 
proteins in the PAX2 promoter in ChIP analysis, because 
individual sonicated fragments were between 200-800 
bp in length and potentially contained multiple SMAD 
binding sites.
SMAD2 or SMAD3 protein-protein  
co-immunoprecipitation
HEK293 cells were transiently transfected with 
the PAX2 expression construct, pCMV-PAX2b, using 
FuGENE. After 42h of transfection, the cells were treated 
with TGF-β1 for 6h to activate SMAD2 and SMAD3. 
The cells were then lysed in non-denaturing lysis buffer 
supplemented with protease inhibitors (Sigma-Aldrich). 
The protein lysates (500 μg per antibody) were precleared 
for 1h at 4°C using Dynabeads® Protein G (Invitrogen), 
followed by immunoprecipitation using mouse anti-
SMAD2/3 (Santa Cruz Biotechnology) or control IgG 
antibodies (Sigma-Aldrich), which was carried out 
overnight at 4°C. This was followed by incubation with 
50 μl Dynabeads for 4h at 4°C, and then the magnetically 
captured protein complexes on Dynabeads were washed 
twice with lysis buffer, and the protein complexes eluted 
by boiling in Laemmli sample buffer (0.24 M Tris-HCl 
pH 6.8, 10% SDS, 40% Glycerol, 20% β-mercaptoethanol, 
0.02% Bromophenol blue) under reducing conditions. 
Proteins were then resolved by SDS-PAGE and analyzed 
by Western blot to investigate SMAD2- or SMAD3-PAX2 
or PAX6 interactions. Following the detection of PAX2, 
the Western blot membrane was stripped and incubated 
with an anti-SMAD2/3 antibody (1:1000, Santa Cruz 
Biotechnology) to detect SMAD2/3 proteins, and then 
the membrane was directly re-probed with anti-PAX6 
antibody (1:100, Developmental Studies Hybridoma 
Bank) to detect PAX6 protein.
PAX2 autoregulation assays
In co-transfection assays, HEK293 cells were 
transiently transfected with one of two PAX2 expression 
constructs (either CMV-PAX2b (PAX2b), or CMV-PAX2c 
(PAX2c) [67], together with the PAX2 promoter-reporter 
plasmid, pGPxp2. Cells were co-transfected with a total of 
600 ng of plasmids, comprising 150 ng of either pCMV-
PAX2b or pCMV-PAX2c, and 150 ng of pGPxp2 with the 
remainder of the transfected plasmid being made up to 
an amount of 575 ng using pCMV empty vector (pCMV-
EV). In some transfections up to 425 ng of either PAX2 
expression vector, or PAX2 promoter-reporter construct 
was transfected, while the concentrations of either the 
expression, or the reporter construct, respectively, were 
maintained at 150 ng, and the amount of pCMV-EV was 
adjusted accordingly to make the total plasmid up to 575 
ng. In addition, pCMV- β-gal (25 ng) was also included in 
all transient transfections to normalize the data to the β-gal 
value. Control transfections included cells only, pGL2 
basic vector alone, CMV-PAX2b or CMV-PAX2c alone, 
and PGL2-basic together with CMV-PAX2b or CMV-
PAX2c, and these were included in each experiment. 
The luciferase activity from “cells only”, and “pGL2 
basic vector alone” was undetectable and is not shown. 
Luciferase activity is represented in Relative Light Units 
(RLU) normalised to the β-gal value.
Online software and statistical analysis
For qRT-PCR analysis, the qBase software 
(version 1.3.5, http://medgen.ugent.be/qbase/) was 
used. For identification of SMAD binding sites in the 
PAX2 promoter, the online web-based tools ConTra v.2 
and TRANSFAC were used. We used ConTra v.2 for 
visualization of SMAD1 or SMAD3 binding sites in 
a region 3.5Kb upstream, or the 5’UTR region of the 
human PAX2 gene on the sequence, NM_003987, with a 
core of 0.90, and similarity matrix of 0.75. Subsequently, 
we used ConTra v.3 for visualization of SMAD3 binding 
sites in the same 3.5Kb region of the same sequence 
(NM_003987), and a core of 0.95 and similarity matrix 
of 0.85, and this identified only the SMAD3 binding site 
previously identified at position -220 upstream of the TSS, 
which was conserved in species from humans to zebrafish.
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